Category: Video

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of…

The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans and explained why we remain extremely…

Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial.   The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in…

Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has…

Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023 to ensure a smooth transition of…

Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director…

Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.